The RNAi TherapeuticsMarket was valued at US$ 1.5 billion in 2021 and is expected to reach US$ 3.2 billion by 2031. The market is expected to register a CAGR of 16.5% from 2023–2031. Rising Research & Development (R&D) activity is likely to remain key RNAi Therapeutics Market trends.
RNAi technique is a new modality for cancer therapy, with several candidates being tested clinically. The significant advantage of RNAi for cancer therapy is its high specificity, with an infinite choice of genes that can be applied to cancer therapy. For example, RNAi therapeutics could interfere with angiogenesis, metastasis, chemoresistance of tumors, and proliferation of cancer cells. Additionally, 10 types of RNAi-based cancer therapeutics have entered the early stage clinical trials, demonstrating the potential capability of RNAi with specific gene-silencing efficacy for cancer treatment. Therefore, the aforementioned factors are responsible for influential RNAi therapeutics market growth during 2021-2031.
Technology, innovation, and smart technological solutions such as continue to influence RNAi therapeutics significantly. RNAi therapeutics in cancer therapy and rising clinical trials for developing of innovative RNAi therapeuticsare the most influential factors responsible for RNAi Therapeutics Market growth. Rising Research & Development (R&D) activity is a key trend for RNAi Therapeutics Market growth. Imaging modalities for RNAi therapeuticswill provide lucrative market opportunity.
Therefore, rising clinical trials for RNAi therapeutics will contribute significantly in the coming years.
Currently, multiple molecular imaging modalities have been applied in RNAi-related research, such as optical imaging (fluorescence and bioluminescence), Magnetic Resonance Imaging (MRI), Magnetic Resonance Spectroscopy (MRS), SPECT, and Positron Emission Tomography (PET). Also, molecular imaging of the therapeutic effects of RNAi is still at the preclinical stage, focussing on the visualization of marker gene expression levels among living animals. These imaging markers are mostly bioluminescent enzymes, where pharmacological activity can be accurately measured. Additionally, MRS also proves useful in evaluating the efficacy of RNAi-based therapies due to its potential to directly detect biological outcomes. Further, the MRS functions better than optical imaging in measuring the chemical shifts to certain compounds (e.g. choline) whose concentration in tissues or tumors can be altered by certain therapeutic interventions. Therefore, R&D activities provide lucrative market opportunities accounting considerable market share in the coming years for RNAi Therapeuticsmarket.
Key segments that contributed to the derivation of the RNAi Therapeutics Market analysis are candidature and services.
The geographic scope of the RNAi TherapeuticsMarket report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.
North America has dominated the RNAi Therapeutics Market. In North America, US accounts considerable share for RNAi therapeutics. Presence of top medical biotechnology and pharmaceutical players in the US. Additionally, presence of Contract Research Organizations (CROs) enhancing Research & Development (R&D) activities are one of the most influential factors responsible for market growth. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.
The regional trends and factors influencing the RNAi Therapeutics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses RNAi Therapeutics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 1.5 Billion |
| Market Size by 2031 | US$ 3.2 Billion |
| Global CAGR (2023 - 2031) | 16.5% |
| Historical Data | 2021-2022 |
| Forecast period | 2023-2031 |
| Segments Covered |
By Molecule Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The RNAi Therapeutics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the RNAi Therapeutics Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The RNAi TherapeuticsMarket is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in them market for RNAi Therapeutics and strategies:
The “RNAi TherapeuticsMarket Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas: